Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA-targeted CAR-T for refractory/relapsed multiple myeloma
NCT03931421Phase 2Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2019
- Primary completion
- Nov 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of BCMA-targeted CAR-T cells in multiple myeloma (MM), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete Remission Rate at 3 months. Status: unknown.
02
Drugs
BCMA-targeted CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03931421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03931421.